What's Happening?
Autoimmunity BioSolutions (ABS), a biotechnology company based in Houston, has successfully closed a $1 million seed extension financing round, increasing its total seed capital to $3.1 million. This funding round was led by Eos BioInnovation and included
participation from several family offices, reflecting strong confidence in ABS's innovative approach to treating autoimmune diseases. The company is developing a personalized, genetically-guided immuno-corrective therapy aimed at normalizing elevated levels of soluble IL7 receptor (sIL7R), which is linked to poor therapeutic responses in autoimmune diseases. The therapy targets a genetically defined subpopulation of patients with a prevalent genetic variant that increases sIL7R expression, associated with more severe disease progression and reduced response to current treatments.
Why It's Important?
The additional funding is crucial for ABS as it aims to reach key clinical milestones and advance its therapy platform. The company's approach is significant because it offers a potential alternative to current treatments that rely on immunosuppressive mechanisms. By targeting a specific genetic variant, ABS's therapy could improve treatment outcomes for patients with autoimmune diseases such as rheumatoid arthritis, lupus nephritis, and type 1 diabetes. This development could have a substantial impact on the biotechnology industry and healthcare sector, offering new hope for millions of patients inadequately served by existing therapies.
What's Next?
With the new capital, ABS plans to complete important animal model work and patient bio-sample analyses in its lead indication of rheumatoid arthritis. The company is poised to build on its scientific momentum and further validate its genetically targeted approach. The participation of seasoned investors suggests a strong belief in the potential of ABS's platform, which could lead to further investment and development opportunities. As ABS progresses, it may attract attention from larger pharmaceutical companies interested in innovative autoimmune therapies.
